Selected research
Industry Research
Interleukin-17 Inhibitors Industry Research Report 2026
Market perspective
The global Interleukin-17 Inhibitors market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Interleukin-17 Inhibitors is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Interleukin-17 Inhibitors is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Interleukin-17 Inhibitors is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Interleukin-17 Inhibitors include Chongqing Genrix Biopharmaceutical, Akesobio, Jiangsu Hengrui Medicine, UCB, Novartis, Eli Lilly and Co., DICE Therapeutics and AstraZeneca, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Interleukin-17 Inhibitors market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Interleukin-17 Inhibitors Market by Company
Chongqing Genrix Biopharmaceutical
Akesobio
Jiangsu Hengrui Medicine
UCB
Novartis
Eli Lilly and Co.
DICE Therapeutics
AstraZeneca
Interleukin-17 Inhibitors Segment by Type
Oral
Injection
Interleukin-17 Inhibitors Segment by Application
Hospital
Clinic
Other
Interleukin-17 Inhibitors Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Interleukin-17 Inhibitors market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Interleukin-17 Inhibitors and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Interleukin-17 Inhibitors.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Interleukin-17 Inhibitors manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Interleukin-17 Inhibitors by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Interleukin-17 Inhibitors in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Oral
- Injection
Applications
- Hospital
- Clinic
- Other
Companies covered
- Chongqing Genrix Biopharmaceutical
- Akesobio
- Jiangsu Hengrui Medicine
- UCB
- Novartis
- Eli Lilly and Co.
- DICE Therapeutics
- AstraZeneca
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Interleukin-17 Inhibitors Market Size (2021-2032)
- 2.2.2 Global Interleukin-17 Inhibitors Sales (2021-2032)
- 2.2.3 Global Interleukin-17 Inhibitors Market Average Price (2021-2032)
- 2.3 Interleukin-17 Inhibitors by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Oral
- 2.3.3 Injection
- 2.4 Interleukin-17 Inhibitors by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Hospital
- 2.4.3 Clinic
- 2.4.4 Other
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Interleukin-17 Inhibitors Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Interleukin-17 Inhibitors Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global Interleukin-17 Inhibitors Revenue of Manufacturers (2021-2026)
- 3.4 Global Interleukin-17 Inhibitors Average Price by Manufacturers (2021-2026)
- 3.5 Global Interleukin-17 Inhibitors Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Interleukin-17 Inhibitors, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Interleukin-17 Inhibitors, Product Type & Application
- 3.8 Global Manufacturers of Interleukin-17 Inhibitors, Established Date
- 3.9 Global Interleukin-17 Inhibitors Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Chongqing Genrix Biopharmaceutical
- 4.1.1 Chongqing Genrix Biopharmaceutical Company Information
- 4.1.2 Chongqing Genrix Biopharmaceutical Business Overview
- 4.1.3 Chongqing Genrix Biopharmaceutical Interleukin-17 Inhibitors Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Chongqing Genrix Biopharmaceutical Interleukin-17 Inhibitors Product Portfolio
- 4.1.5 Chongqing Genrix Biopharmaceutical Recent Developments
- 4.2 Akesobio
- 4.2.1 Akesobio Company Information
- 4.2.2 Akesobio Business Overview
- 4.2.3 Akesobio Interleukin-17 Inhibitors Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Akesobio Interleukin-17 Inhibitors Product Portfolio
- 4.2.5 Akesobio Recent Developments
- 4.3 Jiangsu Hengrui Medicine
- 4.3.1 Jiangsu Hengrui Medicine Company Information
- 4.3.2 Jiangsu Hengrui Medicine Business Overview
- 4.3.3 Jiangsu Hengrui Medicine Interleukin-17 Inhibitors Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Jiangsu Hengrui Medicine Interleukin-17 Inhibitors Product Portfolio
- 4.3.5 Jiangsu Hengrui Medicine Recent Developments
- 4.4 UCB
- 4.4.1 UCB Company Information
- 4.4.2 UCB Business Overview
- 4.4.3 UCB Interleukin-17 Inhibitors Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 UCB Interleukin-17 Inhibitors Product Portfolio
- 4.4.5 UCB Recent Developments
- 4.5 Novartis
- 4.5.1 Novartis Company Information
- 4.5.2 Novartis Business Overview
- 4.5.3 Novartis Interleukin-17 Inhibitors Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Novartis Interleukin-17 Inhibitors Product Portfolio
- 4.5.5 Novartis Recent Developments
- 4.6 Eli Lilly and Co.
- 4.6.1 Eli Lilly and Co. Company Information
- 4.6.2 Eli Lilly and Co. Business Overview
- 4.6.3 Eli Lilly and Co. Interleukin-17 Inhibitors Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Eli Lilly and Co. Interleukin-17 Inhibitors Product Portfolio
- 4.6.5 Eli Lilly and Co. Recent Developments
- 4.7 DICE Therapeutics
- 4.7.1 DICE Therapeutics Company Information
- 4.7.2 DICE Therapeutics Business Overview
- 4.7.3 DICE Therapeutics Interleukin-17 Inhibitors Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 DICE Therapeutics Interleukin-17 Inhibitors Product Portfolio
- 4.7.5 DICE Therapeutics Recent Developments
- 4.8 AstraZeneca
- 4.8.1 AstraZeneca Company Information
- 4.8.2 AstraZeneca Business Overview
- 4.8.3 AstraZeneca Interleukin-17 Inhibitors Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 AstraZeneca Interleukin-17 Inhibitors Product Portfolio
- 4.8.5 AstraZeneca Recent Developments
5 Global Interleukin-17 Inhibitors Market Scenario by Region
- 5.1 Global Interleukin-17 Inhibitors Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Interleukin-17 Inhibitors Sales by Region: 2021-2032
- 5.2.1 Global Interleukin-17 Inhibitors Sales by Region: 2021-2026
- 5.2.2 Global Interleukin-17 Inhibitors Sales by Region: 2027-2032
- 5.3 Global Interleukin-17 Inhibitors Revenue by Region: 2021-2032
- 5.3.1 Global Interleukin-17 Inhibitors Revenue by Region: 2021-2026
- 5.3.2 Global Interleukin-17 Inhibitors Revenue by Region: 2027-2032
- 5.4 North America Interleukin-17 Inhibitors Market Facts & Figures by Country
- 5.4.1 North America Interleukin-17 Inhibitors Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Interleukin-17 Inhibitors Sales by Country (2021-2032)
- 5.4.3 North America Interleukin-17 Inhibitors Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Interleukin-17 Inhibitors Market Facts & Figures by Country
- 5.5.1 Europe Interleukin-17 Inhibitors Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Interleukin-17 Inhibitors Sales by Country (2021-2032)
- 5.5.3 Europe Interleukin-17 Inhibitors Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Interleukin-17 Inhibitors Market Facts & Figures by Country
- 5.6.1 Asia Pacific Interleukin-17 Inhibitors Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Interleukin-17 Inhibitors Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Interleukin-17 Inhibitors Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Interleukin-17 Inhibitors Market Facts & Figures by Country
- 5.7.1 South America Interleukin-17 Inhibitors Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Interleukin-17 Inhibitors Sales by Country (2021-2032)
- 5.7.3 South America Interleukin-17 Inhibitors Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Interleukin-17 Inhibitors Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Interleukin-17 Inhibitors Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Interleukin-17 Inhibitors Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Interleukin-17 Inhibitors Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Interleukin-17 Inhibitors Sales by Type (2021-2032)
- 6.1.1 Global Interleukin-17 Inhibitors Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global Interleukin-17 Inhibitors Sales Market Share by Type (2021-2032)
- 6.2 Global Interleukin-17 Inhibitors Revenue by Type (2021-2032)
- 6.2.1 Global Interleukin-17 Inhibitors Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Interleukin-17 Inhibitors Revenue Market Share by Type (2021-2032)
- 6.3 Global Interleukin-17 Inhibitors Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Interleukin-17 Inhibitors Sales by Application (2021-2032)
- 7.1.1 Global Interleukin-17 Inhibitors Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global Interleukin-17 Inhibitors Sales Market Share by Application (2021-2032)
- 7.2 Global Interleukin-17 Inhibitors Revenue by Application (2021-2032)
- 7.2.1 Global Interleukin-17 Inhibitors Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Interleukin-17 Inhibitors Revenue Market Share by Application (2021-2032)
- 7.3 Global Interleukin-17 Inhibitors Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Interleukin-17 Inhibitors Value Chain Analysis
- 8.1.1 Interleukin-17 Inhibitors Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Interleukin-17 Inhibitors Production Mode & Process
- 8.2 Interleukin-17 Inhibitors Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Interleukin-17 Inhibitors Distributors
- 8.2.3 Interleukin-17 Inhibitors Customers
9 Global Interleukin-17 Inhibitors Analyzing Market Dynamics
- 9.1 Interleukin-17 Inhibitors Industry Trends
- 9.2 Interleukin-17 Inhibitors Industry Drivers
- 9.3 Interleukin-17 Inhibitors Industry Opportunities and Challenges
- 9.4 Interleukin-17 Inhibitors Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst